Opinion

Video

Overview of Efficacy and Safety Data for Current CLL Treatment Options

A general overview of efficacy and safety data for current treatment options for patients with chronic lymphocytic leukemia.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Image of Andy.
July 13th 2025

Finding Comfort and Connection in the Chemo Lounge

Andy Winnegar
During treatment for chronic lymphocytic leukemia and autoimmune anemia, I found relief and encouragement in a caring conversation with my oncology nurse.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Linda Cohen is a survivor of small lymphocytic lymphoma and was diagnosed in 2009. Catch up on all of Linda's blogs here!
July 1st 2025

A Cocktail and the Freedom I Never Expected With Cancer

Linda Cohen
After years off medication, I finally enjoyed a grapefruit cocktail — symbolizing freedom from cancer’s constant shadow and hope for the future.
CURE Talks Cancer podcast
December 31st 2020

The Treatment Journey of a Patient with CLL

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.
Breyanzi demonstrated a 95.5% response rate among in relapsed/refractory marginal zone lymphoma: © stock.adobe.com.
June 17th 2025

Breyanzi Shows Durable Responses in R/R Marginal Zone Lymphoma

Spencer Feldman
Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a durable safety.
FDA approves new Brukinsa tablet for five blood cancers: © stock.adobe.com.
June 12th 2025

FDA Approves Brukinsa Tablet For Various Blood Cancers

Spencer Feldman
FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.